# Rhinostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rhinostics

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.rhinostics.com
- Latest round: Series A (Jun 7, 2022)
- Investors on record: 3

## About

Based in Massachusetts, US, Rhinostics, Inc. was founded in 2020 by co-founders Michael Springer Ph.D and Richard Novak Ph.D. The FDA (Food and Drug Administration) has approved the RHINOsticTM product as a Class I exempt medical device. In December 2020, the company raised seed funding, followed by Series A funding in March 2021.

Rhinostics' nasal swab collection kits incorporate a one-piece cap-and-swab combination with a barcode on the bottom of the collection vial for automated de-capping and swab removal, as well as simultaneous scanning of several vials.

The company generates revenue by offering a system that allows for sample collection, quick accessioning, and automated cap removal, which can be coupled to high throughput Covid-19 tests from laboratory operations.

## Funding rounds

- Series A, Jun 7, 2022 — Shadow Ventures, Avestria Ventures, Covid Apollo Project
- Series A, Mar 11, 2021 — Covid Apollo Project
- Seed, Dec 17, 2020 — Avestria Ventures

## Investors

- Avestria Ventures (https://capitalatlas.ai/funds/avestria-ventures) — Seed, Series A
- Covid Apollo Project (https://capitalatlas.ai/funds/covid-apollo-project) — Series A
- Shadow Ventures (https://capitalatlas.ai/funds/shadow-ventures) — Series A